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Objective: Multiple gene transfer might permit modulation of concurrent biochem-
ical pathways involved in lung graft ischemia-reperfusion injury. In this study we
analyzed whether recipient intramuscular naked plasmid cotransfection of trans-
forming growth factor 1 and interleukin 10 would result in amelioration of lung
graft ischemia-reperfusion injury.
Methods: Forty-eight hours before transplantation, 6 groups (n  6) of F344 rats
received intramuscular injection of naked plasmid encoding chloramphenicol
acetyltransferase, chloramphenicol acetyltransferase plus -galactosidase, trans-
forming growth factor 1, interleukin 10, or transforming growth factor 1 plus
interleukin 10 or were not treated. Donor lungs were flushed and stored for 18 hours
at 4°C before transplantation. Twenty-four hours later, grafts were assessed imme-
diately before the animals were killed. Arterial oxygenation, wet/dry ratio, myelo-
peroxidase, and proinflammatory cytokines (interleukin 1, tumor necrosis factor ,
interferon , and interleukin 2) were measured, and immunohistochemistry was
performed.
Results: For lung graft function, the arterial oxygenation was considerably higher in
the cotransfected group receiving transforming growth factor 1 plus interleukin 10
compared with that in all other groups (P  .03). The wet/dry ratio, reflecting lung
edema, was reduced in the cotransfected group compared with that in control
animals (nontreated, P  .02; chloramphenicol acetyltransferase, P  .03; chlor-
amphenicol acetyltransferase plus -galactosidase, P  .01). Myeloperoxidase,
which measures neutrophil sequestration, was also reduced with cotransfection
compared with that seen in control animals (P  .03). All proinflammatory cyto-
kines were decreased in the cotransfected group compared with those in all other
groups (interleukin 1, P  .04; tumor necrosis factor , P  .002; interferon , P
 .0001; interleukin 2, P  .03). These results indicate that cotransfection provides
a synergistic benefit in graft function versus either cytokine alone, neutrophil
sequestration, or inflammatory cytokine expression. Immunohistochemistry showed
positive staining of transforming growth factor 1 plus interleukin 10 in type I and
II pneumocytes and localized edema fluid.
Conclusions: Recipient intramuscular naked plasmid cotransfection of transforming
growth factor 1 and interleukin 10 provides a synergistic effect in ameliorating
lung reperfusion injury after prolonged ischemia.
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Gene therapy has evolved as a potentialnew alternative therapy for several patho-logic conditions, such as autoimmune dis-eases1 and malignant tumors.2 It also rep-resents a new modality to modulateischemia-reperfusion (I/R) injury in lung
transplantation. Severe graft dysfunction caused by I/R in-
jury occurs in 10% to 20% of lung transplant recipients and
results in progressive hypoxemia, decreased pulmonary
compliance, and high permeability pulmonary edema,
which often are associated with a need for prolonged inten-
sive care.3,4 I/R injury leading to severe graft dysfunction is
also the most common cause for mortality within the first
month after lung transplantation.3
The inflammatory cascade of I/R injury is a dynamic
combination of events. During the period of ischemia before
reperfusion, the classical complement pathway is activated,
and macrophages are attractedand release preformed cyto-
kines, such as tumor necrosis factor  (TNF-).5 These
cytokines in turn increase the expression of neutrophil ad-
hesion molecules on endothelial cells.5,6 Neutrophils then
contribute to I/R injury by generating oxygen-derived free
radicals, releasing proteases, and secreting arachidonic acid
metabolites and other proinflammatory mediators.7
Interleukin 10 (IL-10) is a potent inhibitor of inflamma-
tory cytokine production. It is normally produced by mac-
rophages and T lymphocytes.8 Two targets of IL-10 inhibi-
tion are TNF- and interferon  (IFN-). Because
macrophage cytotoxicity is induced by IFN- and requires
TNF- as a costimulatory signal, IL-10 modulates macro-
phage activity by decreasing TNF-.9 Furthermore, IL-10
strongly inhibits natural killer cells that produce IFN-,
leading to decreased IFN- production. Thus, by decreasing
TNF- and IFN-, IL-10 reduces macrophage cytotoxicity
and plays a role in decreasing I/R injury.9
Transforming growth factor 1 (TGF-1) is a pleiotropic
protein with unique and potent immunoregulatory proper-
ties produced by several cells, including lymphocytes and
macrophages.10 It works in concert with IL-10 to block the
activation of macrophages and T helper cells.11,12 For ex-
ample, both TGF-1 and IL-10 enhance production of the
interleukin 1 (IL-1) receptor antagonist, a potent anti-in-
flammatory mediator.10
Several approaches using the delivery of gene vectors
have been successful by producing transgene expression in
experimental studies for lung transplantation.13-19 Transfec-
tion of viral vectors encoding heat shock protein 70, IL-10,
and endothelial nitric oxide synthase has been shown to
decrease lung graft I/R injury.14-16 Intramuscular injection
of nonviral vectors encoding TGF-1 has also been shown
to attenuate the proinflammatory response in I/R injury.17
In this study we demonstrate successful transgene ex-
pression after intramuscular naked plasmid gene transfer of
viral IL-10 (vIL-10) and TGF-1 and show that their co-
transfection results in amelioration of lung graft I/R injury.
Material and Methods
Animals
Male F344 rats (Harlan Sprague Dawley Inc, Indianapolis, Ind)
weighing between 230 and 250 g were used in all experiments.
Protocols were approved by the Animal Studies Committee at
Washington University. Animals received humane care in compli-
ance with the “Principles of Laboratory Animal Care” formulated
by the National Society for Medical Research and the “Guide for
the Care and Use of Laboratory Animals” prepared by the National
Academy of Sciences and published by the National Institutes of
Health (National Institutes of Health publication No. 85-23, re-
vised 1996).
Plasmids
The plasmid viral IL-10 (pCMVievIL-10), kindly provided by Dr
Jonathan Bromberg (Mount Sinai School of Medicine, New York,
NY), consists of a human cytomegalovirus immediate-early pro-
moter and enhancer followed by the tripartite leader from Epstein-
Barr virus, a hybrid intron constituted by IL-10 (BCRF1-vIL10),
and a polyadenylation signal from bovine growth hormone. Endo-
toxin units tested were lower than 1 EU/mL (EU  1).
The plasmid TGF-1 (pMP6A-TGF1-Active) was created in
our laboratory, encoding the rodent active fragment of TGF-1 by
mutated cysteine in serine in position 223 and 225 of the TGF-1
cDNA. The mutated TGF-1 cDNA, kindly provided by Dr Debra
A. Hullett (Department of Surgery, University of Wisconsin, Mad-
ison, Wis), was amplified by means of polymerase chain reaction
with Ampli-TAQ polymerase (Perkin Elmer Applied Biosystems,
Foster City, Calif) from an adenovirus encoding his sequence.
Primers for the amplification were constructed with NheI termi-
nals. The amplified cDNA was then cloned in the NheI cloning site
of the adeno-associated plasmid pMP6A with a cytomegalovirus
initial promoter and an SV40 polyadentylation signal sequence,
also kindly provided by Dr Jonathan Bromberg. Correct orienta-
tion was checked by means of BamHI digestion. Adequate primers
were then constructed for the sequencing of the mutated TGF-1
cDNA by the Protein Chemistry and Nucleic Acid Laboratory at
Washington University. Purity of the plasmid after mega preps
(Endo-free Mega Kit; Quiagen Inc, Valencia, Calif) was tested at
Charles River Laboratories (Charleston, SC), and the endotoxin
units were approximately 10 EU/mL (EU  10).
Study Design
Nontransplant setting. Thirty-six rats divided into 4 groups
(n  3 each for 3 time points) received 1000 g of vIL-10,
mutated TGF-1, or both by means of separate injections of 1 mL
in each gastrocnemius muscle. Plasmids were suspended in 0.9%
saline solution, and control groups were injected with 1 mL of
saline solution.
All groups were killed 24, 48, or 168 hours after treatment.
Muscles were immediately frozen in liquid nitrogen at 70°C.
Blood was collected and centrifuged at 1000g for 30 minutes at
4°C. The plasma obtained was divided into 2 vials: one was stored
at 70°C for enzyme-linked immunosorbent assay (ELISA) anal-
Cardiothoracic Transplantation Daddi et al
260 The Journal of Thoracic and Cardiovascular Surgery ● August 2002
TX
ysis, and the other underwent a second cycle of centrifugation
(15,000g for 15 minutes) for TGF-1 expression measurement.20
Transplant setting. Thirty-six rats divided into 6 groups (n 
6 each) received intramuscular injection in the gastrocnemius
muscle of 1000 g of plasmid diluted in 1 mL of saline solution
with chloramphenicol acetyl transferase (CAT); CAT and -ga-
lactosidase (-Gal); or vIL-10, TGF-1, or vIL-10 and TGF-1.
CAT and -Gal are nonfunctional reporter genes used as plasmid
controls. One more control group was not treated with any vector.
Cotransfection groups used separate intramuscular injections in
contralateral muscles.
Eighteen hours before transplantation, donors were harvested
as previously described.14-16 In brief, donors were anesthetized
with intraperitoneal pentobarbital of 0.3 mL (30 mg/kg), intubated
with a 14-gauge catheter by means of tracheotomy, and mechan-
ically ventilated (model 683; Harvard Apparatus Co, South Natick,
Mass) with room air. Lungs were flushed with 20 mL of cold low
potassium dextran 1% glucose solution through the main pulmo-
nary artery. The heart-lung block was removed, and the pulmonary
artery, pulmonary vein, and left main bronchus were prepared with
polyethylene cuffs and preserved at 4°C for 18 hours.
Forty-eight hours after intramuscular treatment, the recipients
underwent transplantation. After anesthesia with subcutaneous in-
jection of ketamine (25 mg/kg), atropine (30 mg/kg), and halo-
thane inhalation (0.5%-1%) from orotracheal intubation, a left
thoracotomy was performed. The left pulmonary vessels and main
bronchus were anastomosed by the previously described cuff tech-
nique.21 Ventilation and perfusion were restored, and a temporary
drainage chest tube was placed, which was subsequently removed
in the incubator (Intensive Care System; Thermocare Inc, Incline
Village, Nev) after recovery from anesthesia.
Twenty-four hours after transplantation, the recipients were
killed. Animals were reanesthetized by means of intraperitoneal
pentobarbital injection and their lungs were ventilated with 100%
oxygen. Median laparosternotomy was performed, and the right
hilum was clamped. The animals’ lungs were ventilated for 5
minutes by means of a tidal volume of 1.5 mL, peak end-expira-
tory pressure of 1 cm H2O, and rate of 100 breaths/min. Blood
samples were then collected from the ascending aorta. The left
lung was frozen in liquid nitrogen and stored in 3 separate sec-
tions: the upper section was used for ELISA; the middle section
was used for myeloperoxidase (MPO) assay; and the lower section
was weighed, dried at 70°C for 48 hours, and then reweighed for
calculation of the wet/dry ratio (W/D). A portion of the native right
lung of the donor was taken for comparison.
Six additional recipient rats were intramuscularly cotransfected
with vIL-10 plus TGF-1 (n  3) or not transfected (n  3) and
underwent the same transplant procedure as above for immuno-
histochemistry assessment. Their left lungs were flushed through
the main pulmonary artery with saline solution at a pressure of 20
cm H2O and then fixed with Histochoice (AMRESCO, Solon,
Ohio). No functional or efficacy data were obtained from these
animals.
Assessment
MPO. Quantitative lung homogenate MPO activity as a mea-
sure of neutrophil sequestration was determined as previously
described,22 with some modification.14 Optical density was mea-
sured at 460 nm with a spectrophotometer (Genesis 5; Spectronic
Instruments, Inc, Rochester, NY). For each sample, the 5-minute
reading was subtracted from the 20-minute reading and standard-
ized to the total protein present in that sample (BCA Protein Assay
Kit; Pierce, Rockford, Ill). MPO enzyme activity is expressed in
units on the basis of the amount of protein required to effect a 
change of 1 optical density unit per minute at room temperature.
ELISA. All muscle and lung tissue studied was homogenized
in lysis solution containing 100 mmol/L potassium phosphate (pH
7.8), 0.2% Triton X-100 with pepstatin A (5 g/mL; Roche Mo-
lecular Biochemicals, Mannheim, Germany), and protease inhibi-
tor cocktail (Complete mini, Roche Molecular Biochemicals). The
homogenate was incubated for 15 minutes at room temperature
and then centrifuged at 15,000 rpm for 15 minutes. The superna-
tant was collected and analyzed for proinflammatory cytokines.18
TGF-1 protein activity in muscle and plasma was detected by
means of ELISA according to the protocol of R&D Systems
(Minneapolis, Minn) for human TGF-1, which is also cross-
reactive to rat and mouse. The procedure to activate the latent form
of TGF-1 in the ELISA kit was not used for the detection of
active TGF-1.
The presence of vIL-10 was detected according to the BD
Pharmingen (San Diego, Calif) cytokine and chemokine ELISA
protocol, with few modifications. In brief, the purified rat mono-
clonal antibody for vIL-10 (BD Pharmingen) was diluted to 2
g/mL in a ligand solution (0.1 mol/L Na2HPO4 at pH 9.0). After
overnight incubation at 4°C in a 96-well plate (MaxiSorp Surface;
Nalge Nunc Int, Rochester, NY), the wells were incubated with
blocking buffer (1% bovine serum in phosphate-buffered saline
solution [PBS]) for 2 hours to prevent nonspecific binding. After
washing with PBS-Tween, all recombinant vIL-10 standards (BD
Pharmingen) and the samples were added for 3 hours. After
washing with PBS-Tween-20, the wells were incubated with bio-
tinylated anti-vIL-10 antibody (BD Pharmingen) and streptavidin-
horseradish peroxidase. The colorimetric reaction was activated by
the substrate solution (2,2-azino-bis-3-etilenbenzotazolin-6-sul-
fonic acid) and read after 40 minutes (optical density, 405 nm).
The quantitative expression of proinflammatory cytokines (IL-
1, IL-2, TNF-, and IFN-) was performed according to the
protocols of R&D Systems kits.
All samples were standardized to the total protein with the
BCA kit (Pierce).
Immunohistochemistry. Immunohistochemistry, as previously
described,23 was performed according to the protocol of the Tyra-
mide Signal Amplification kit (NEN Life Science Products, Bos-
ton, Mass). In brief, slides were incubated for 4 hours at room
temperature with biotinylated rat anti-mouse/anti-human TGF-1
antibody (BD Pharmingen) at 1:40 dilution in TNB buffer (Block-
ing Reagent in 100 mmol/L Tris and 500 mmol/L NaCl, pH 7.4)
and 0.1% saponin. Slides were washed in TBS (100 mmol/L Tris
and 500 mmol/L NaCl/0.2% Triton X, pH 7.4) and 0.1% saponin.
Slides were then incubated with streptavidin-horseradish peroxi-
dase for 30 minutes, followed by biotinyl tyramide for 10 minutes.
Finally, slides were incubated for 30 minutes with streptavidin-
alkaline phosphatase. Chromogenic detection for TGF-1 was
performed with Vector Blue Alkaline Phosphatase Substrate (Vec-
tor Laboratories, Burlingame, Calif) in 100 mmol/L Tris, pH 8.2,
including 5 mmol/L levamisole and 50 L of Tween-20. For
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subsequent double staining to detect vIL-10, slides were washed
with deionized water. The blocking step in Super Blocking Buffer
was performed. Slides were incubated overnight at room temper-
ature with biotinylated rat antiviral IL-10 antibody (BD Pharmin-
gen) diluted 1:20 in TNB Buffer/0.1% saponin. The detection
method was performed as stated above, except that streptavidin-
horseradish peroxidase was substituted for streptavidin-alkaline
phosphatase in the final step. Slides were developed for 5 minutes
with Vector NovaRed Substrate (Vector Laboratories) and trans-
ferred to TE buffer (tris-ethylenediamine tetraacetic acid) at pH 8.0
to stop the reaction. Slides were counterstained with methyl green
nuclear (Vector Laboratories) for 5 minutes and permanently
mounted with Cytoseal 60 (Stephens Scientific, Kalamazoo,
Mich).
The pattern of protein expression and histology using hema-
toxylin and eosin staining was assessed by a blinded observer
(J.H.R.).
Statistics
Parametric data were analyzed by means of 1-way analysis of
variance and the Fisher post hoc multiple comparison test. Values
are reported as means  SD. Data not normally distributed were
converted to a square root transformation before the analysis of
variance was performed.
Results
Nontransplant Setting
vIL-10. A significant increase was detected in muscle
and plasma after intramuscular administration of vIL-10 and
vIL-10 plus TGF-1 at 48 hours after administration com-
pared with at 24 or 168 hours after administration (P 
.002, Fig 1, A; P  .008, Fig 1, B). On the basis of these
results, 48 hours before transplant was chosen as the time
point for intramuscular injection of vIL-10 naked plasmid in
the I/R injury model.
TGF-1. Muscle expression (Fig 1, C) after 24 and 48
hours was significantly increased in the cotransfected
groups compared with that seen in control animals (P 
.0001) or that seen in groups transfected with TGF-1 alone
(P  .0086 to 24 hours and P  .0027 to 48 hours).
Figure 1. vIL-10 expression in muscle (A) and in plasma (B) and TGF-1 expression in muscle (C) and in plasma (D).
Muscle and plasma were collected at 24, 48, and 168 hours after intramuscular injection and were assayed by
means of ELISA.
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Similarly, in plasma (Fig 1, D) significant differences were
observed between cotransfected groups and control animals
(24 and 48 hours, P  .0001) or with groups transfected
with TGF-1 alone (24 and 48 hours, P  .0001). As with
vIL-10, these results support selecting 48 hours before
transplant as the optimum intramuscular injection time for
TGF-1 in the I/R injury model. Interestingly, there were no
differences in the TGF-1 levels between the 24- or 48-hour
cotransfected groups in both muscle and plasma.
Transplant Setting
Pao2. Lungs from the cotransfected group had superior
Pao2 levels (Table 1) compared with those of the nontreated
control group (P  .0002), the CAT group (P  .0001), or
the CAT plus -Gal group (P  .0001) and those of groups
treated with TGF-1 alone (P  .0005) or vIL-10 alone
(P  .011). Cotransfection provides a synergistic benefit
versus either cytokine alone in graft function as measured
by Pao2.
W/D ratio. The W/D ratio, which reflects lung edema
(Table 1), was significantly lower among the TGF-1, vIL-
10, vIL-10 plus TGF-1, and control groups (P  .03, P 
.015, and P  .028, respectively). Furthermore, there was
no difference between the above study groups and normal
flushed nontransplanted lungs (P  .8). This indicates that
the flushing process does not affect the W/D ratio, and
cotransfection provides a benefit in reducing lung edema.
However, cotransfection was not superior to either cytokine
alone in reducing the edema.
MPO. MPO activity, which reflects neutrophil seques-
tration (Table 1), was decreased significantly in the cotrans-
fected group versus that seen in the no treatment, CAT, or
CAT plus -Gal groups (P  .0028, P  .0023, and P 
.0017, respectively). Also, vIL-10 had significantly de-
creased MPO versus that seen in the no treatment, CAT, or
CAT plus -Gal groups (P  .03, P  .034, and P  .026,
respectively). These results indicate that vIL-10 and vIL-10
plus TGF-1 reduce neutrophil sequestration but not
TGF-1 alone.
Proinflammatory cytokines. For this analysis, we added
2 groups: flushed normal nontransplanted lungs and flushed
transplanted lungs after 1 hour of ischemia at 4°C (1 hour,
no transfection).
IL-1 levels (Table 2 and Fig 2, A) in the cotransfected
group were significantly lower compared with those in all
TABLE 1. Isolated left lung assessment
Treatment in the
transplanted rodents
(n  6)
Isolated left lung graft assessments
PaO2 (mm Hg) W/D ratio MPO (OD/min/mg protein)
18 hrs, no treatment 105.6 75.4 8.7 2.2 0.414 0.245
CAT 76.01 48.4 8.1 1.9 0.435 0.346
CAT  -Gal 64.7 43.5 8.6 1.7 0.463 0.468
TGF-1 127.03 45.2 5.9 0.6* 0.223 0.111
IL-10 185.6 93.3* 6.1 1.1* 0.135 0.05*
TGF-1  IL-10 311.6 137.2* 5.6 0.5* 0.068 0.045*
All values are compared with those of a normal, nontransplanted lung (5.54 0.66). All data are expressed as means SD (*P .05). OD/min/mg protein,
Interval change in optical density units per minute per milligram of tissue protein; 18 hr, no transfection, lung underwent 18 hours of cold ischemia, followed
by transplantation into a nontreated recipient.
TABLE 2. Cytokine production in transplanted lung grafts
Treatment in the transplanted
rodents (n  6)
Cytokine production (pg/100 g total protein)
IL-1 TNF- IFN- IL-2
Normal lungs 7.5 2.2 ND ND 2.21 0.41
1 hr, no transfection 22.5 4.9 0.33 0.28 0.64 0.13 3.32 1.76
18 hrs, no transfection 24.02 18.5 0.77 0.45 0.69 0.06 4.76 5.52
CAT 21.9 9.7 0.81 0.36 1.25 0.4 4.59 3.42
CAT  -Gal 24.3 10.01 0.82 0.35 0.77 0.35 5.36 5.29
TGF-1 24.3 8.9 0.48 0.13* 0.59 0.27 0.37 0.32*
vIL-10 19.5 8.8 0.4 0.15* 0.34 0.13* 0.35 0.16*
TGF-1  IL-10 9.2 5.3* 0.076 0.12* 0.02 0.03* 0.25 0.3*
All data are expressed as means  SD (*P  .05). 1 or 18 hrs, no transfection, Lung underwent 1 or 18 hours of cold ischemia, followed by transplantation
into a nontreated recipient; ND, not detected.
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other control and study groups (1 hour, no transfection, P
.0039; 18 hours, no transfection, P  .0063; CAT, P 
.0073; CAT plus -Gal, P  .0021; TGF-1, P  .0021;
and vIL-10, P  .022). However, transfection with either
cytokine alone did not significantly reduce the IL-1 levels.
Also, no difference was noted between cotransfected and
normal nontransplanted lungs (P  .688).
TNF- (Table 2 and Fig 2, B) was undetectable in
normal nontransplanted lungs. vIL-10 significantly reduced
TNF- levels versus those in the 18 hours with no trans-
fection, CAT, and CAT plus -Gal groups (P  .024, P 
.012, and P  .011, respectively), whereas TGF-1 signif-
icantly reduced TNF- levels versus those seen in the CAT
and CAT plus -Gal groups (P  .039 and P  .034,
respectively). Each cytokine was able to reduce the TNF-
expression, but cotransfection synergistically lowered the
TNF- expression compared with that seen in all control
and study groups (P  .0001 for all groups).
IFN- (Table 2 and Fig 2, C) was also undetectable in
normal nontransplanted lungs and was not significantly
different from levels in the cotransfected group (P  .2).
Like IL-1, cotransfection leads to a normal cytokine bal-
ance with respect to IFN-. In addition, the cotransfected
group had a significantly lower IFN- level compared with
all control and study groups (P  .0001 for all groups).
TGF-1 was only significantly decreased compared with
that in the CAT group (P  .0001), and vIL-10 was signif-
icantly decreased when compared with the TGF-1 group
(P  .036), as well as the flushed transplanted lungs, CAT,
and CAT plus -Gal control groups (P  .008, P  .0001,
and P  .0001, respectively). This shows that IL-10 is
effective in reducing IFN-, whereas TGF-1 is not. Yet the
cotransfection results indicate that TGF-1, by possibly
augmenting IL-10 levels, allows for a greater reduction in
IFN- levels.
Last, IL-2 expression (Table 2 and Fig 2, D) was very
low in the 3 study groups of TGF-1, vIL-10, and vIL-10
plus TGF-1 and was significantly reduced compared with
that in the following control groups: 1 hour, no transfection;
18 hours, no transfection; CAT; and CAT  -Gal, respec-
Figure 2. Proinflammatory cytokine expression in transplanted lungs: IL-1 (A), TNF- (B), IFN- (C), and IL-2 (D).
All samples were collected 24 hours after transplantation and were assayed by means of ELISA.
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tively (P  .028, P  .0048, P  .0022, and P  .001 for
TGF-1 and vIL-10 alone; P  .01, P  .001, P  .0007,
and P  .0002 for vIL-10 plus TGF-1). There does not
appear to be any synergism exhibited with cotransfection
with respect to IL-2 levels, yet either cytokine alone is
extremely effective in reducing IL-2.
Histology. Hematoxylin and eosin staining in cotrans-
fected lungs showed moderate edema and mild interstitial
neutrophil infiltration when compared with that seen in
normal lungs (Fig 3, A). Severe edema and moderate interstitial
infiltration of neutrophils with rare microabscesses and hyaline
membranes appears in nontreated lungs (Fig 3, B).
Results of immunohistochemistry double staining for
vIL-10 and TGF-1 was negative in normal and nontreated
lungs (Fig 4, C and D). On the other hand, cotransfected
lungs had a light diffuse staining of edema fluid for vIL-10
(Fig 4, B) and some localized areas of type II cells (Fig 4,
B). Also, most of the type I and II alveolar epithelial cells
were stained positive for TGF-1 (Fig 4, A, for both and Fig
4, B, for type I).
Figure 3. A, Hematoxylin and eosin staining for cotransfected treated lungs showing intact airways, no inflam-
mation, no exudates, and mild edema. (Original magnification 100.) B, Hematoxylin and eosin staining of
nontreated lungs showing interstitial inflammation, few alveolar neutrophils, and fibrin exudates in alveolar ducts
and spaces consistent with acute pneumonitis. (Original magnification 100.)
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Discussion
I/R injury involves a series of events with early and late
phases. The early phase is neutrophil independent, whereas
neutrophils mediate most of the injury in the late phase.5
During reperfusion of ischemic tissue, the classical comple-
ment pathway is activated, and the potent chemotactic fac-
tors C5a and C1q are released. These binding proteins
attract macrophages. Macrophage migration is also partially
mediated by activated TGF-1 and macrophage chemoat-
tractant protein 1 released from injured cells.5 Macrophages
then release the preformed cytokines TNF-, IL-1, and
IL-6, which increase the expression of neutrophil adhesion
molecules, such as intercellular adhesion molecule 1, on
endothelial cells.5,6 The chemokines IL-8 and macrophage
inflammatory protein 1 also mediate neutrophil chemotaxis.
The late phase of I/R injury occurs several hours after this
inflammation begins.24 Normally, neutrophils are more con-
centrated within the pulmonary capillaries than in systemic
blood.24,25 The inflammatory mediators, such as C5a,
TNF-, and IL-8, cause neutrophils to become less deform-
able and foster pulmonary capillary sequestration.25 The
sequestered neutrophils adhere to the capillary endothelium,
migrate into the lung parenchyma and air spaces, and con-
tribute to I/R injury by generating oxygen-derived free
radicals, releasing proteases, and secreting arachidonic acid
metabolites and other proinflammatory mediators.7,25
In this study we evaluated the effects of IL-10 and
TGF-1 and their anti-inflammatory role in lung transplant
I/R injury. Cellular IL-10 is regularly produced during in-
flammatory processes by monocytes, macrophages, and T
Figure 4. Positive double-staining immunohistochemistry of cotransfected lungs with TGF-1 positive staining,
showing type I (arrow I, A and B) and type II (arrow II, A) pneumocytes in dark blue. Viral IL-10 positive staining
(B) in localized edema fluid (**) in brick red and type II pneumocytes (arrow II). Superimposed positive staining
for both cytokines represents edema fluid appearing purple (*) in A. The normal (C) and 18-hours ischemic
nontreated lungs (D) were negative after double staining. (Original magnification 200.)
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lymphocytes.8 It inhibits the production of proinflammatory
cytokines, such as IL-1, IL-2, IL-6, IL-12, and TNF-, and
inhibits natural killer cell production of IFN-. Conversely,
IL-10 might have an important role in the differentiation of
mastocytes.8,26 Human IL-10, similar to cellular IL-10, has
anti-inflammatory effects.26,27 Viral IL-10 is structurally
similar to cellular IL-10 in the sequence encoding the ma-
ture protein. It also inhibits the activity of the cytokines and
downregulates the expression of major histocompatibility
complex II on the surface of monocytes. Because vIL-10
does not possess the costimulatory effect of cellular IL-10
on mastocytes, it is an effective immunosuppressant
agent.12,26,28,29
Similar to IL-10, TGF-1 plays an important role in the
modulation of the inflammatory process and in several other
processes, such as embryonic development, tumorigenesis,
wound healing, and fibrosis.30 Its immunosuppressive ac-
tivity is related to antagonizing inflammatory cytokines,
such as IL-1, TNF-, and IFN-.12,29 Gene transfer strate-
gies of IL-10 and TGF-1 are important because of their
short half-life when administered in vivo. Human studies
have demonstrated a half-life of approximately 2 to 5 hours
when IL-10 is given intravenously or subcutaneously.31
Animal studies show a half-life of 100 minutes for the latent
form of TGF-1 compared with 2 to 3 minutes for the active
form.19 Conversely, a single application of IL-10 or TGF-1
gene transfer might provide significant protein expression to
reduce I/R injury. Furthermore, unlike other types of injury,
gene transfer in experimental and clinical lung transplanta-
tion can provide cytokine expression before the onset of I/R
injury.
The naked plasmid vector was chosen for gene delivery
in our model for several reasons. We previously reported
that muscle expression of gene transfer products using ad-
enoviral vectors might enter the bloodstream and have ben-
eficial effects in acute lung rejection.32 The viral vector has
a higher capability to transfect cells compared with that of
naked plasmid but might affect the pretransplant and post-
transplant recovery secondary to the possible inflammatory
side effects and the potential immunologic response of the
recipient to the vector. Despite the shortcomings of lower
expression, lower transfection efficiency, and high concen-
tration necessary to have a beneficial response, the advan-
tages of using plasmids are (1) no systemic toxicity and
consequently no side effects,33-35 (2) the possibility of en-
hancing gene transfer efficiency and transgene expression
with several injections,29 (3) relatively lower cost, and (4)
easy applicability in the clinical setting by means of simple
intramuscular administration. We have shown (unpublished
data), using intramuscular injection of CAT naked plasmid,
that the gastrocnemius muscle was markedly transfected
compared with the heart, lung, kidney, spleen, or liver. This
supports that naked plasmid use produces no systemic tox-
icity or side effects. Also, we found elevated CAT protein
expression in muscle for 7 days. This supports the advan-
tage of a single intramuscular injection of naked plasmid
over intravenous or pharmacologic delivery of cytokines.
In the expression phase of the study, the data show that
at least 48 hours after injection are required for both anti-
inflammatory cytokines to be sufficiently present in the
rodent system. We also found a marked increase in TGF-1
expression in the cotransfected groups compared with in the
groups treated with either cytokine alone. This suggests that
vIL-10 augments TGF-1 muscle and plasma expression.
We also found that TGF-1 expression was significantly
increased after both 24 and 48 hours after injection. This
implies that one could perform intramuscular injection of
TGF-1 and vIL-10 24 hours before transplantation and
possibly obtain similar results with respect to reducing I/R
injury as those found when injections are performed 48
hours before transplantation. Also, this suggests that co-
transfection allows for earlier recipient plasmid administra-
tion because the delivery of 2 agents will augment and
expedite each other’s expression compared with the deliv-
ery of a single agent.
In contrast, IL-10 expression 24 hours after injection was
not significantly increased compared with that 48 hours
after injection. The main factor that might decrease exoge-
nous IL-10 expression 24 hours after injection is the low
transfection efficiency in muscle fibers. Another factor is
related to the short systemic half-life of IL-10. In contrast,
TGF-1 has a very short life,32 but its plasma levels corre-
late with muscle levels, leading us to believe that what is
being produced in muscle is remaining intact in plasma.
This could be due to the large volume of plasmid used that
creates damage to the muscle fibers and allows for greater
transfection efficiency.27,36
Immunohistochemistry results show type I and II pneu-
mocytes are seen in transplanted lungs stained for TGF-1
after only intramuscular injection of plasmid. Bellocq and
colleagues37 found that reactive oxygen intermediates might
increase TGF-1 release from human epithelial alveolar
cells in vitro. Therefore, the reperfusion period after trans-
plantation might provide the stimulus for such oxygen in-
termediates to activate alveolar cells to release and stain for
TGF-1 in our model. One hypothesis to explain this finding
is that TGF-1 released systemically from muscle fibers
might be taken up by type I or II pneumocytes. Another
possibility is that inflammatory cells, such as macrophages,
infiltrate the lung graft to produce either endogenous
TGF-1 or to stimulate alveolar cells to produce TGF-1.27
Wolff and colleagues34 and Davis and coworkers33 have
demonstrated the efficacy of the naked plasmid for direct
gene transfer into rodent skeletal muscle. However, the
mechanisms for how plasmids enter muscle fibers38 or how
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a cytokine might augment the activity of another cytokine
remain unsolved.35,36
Attenuation of lung I/R injury was noted after the intra-
muscular cotransfection treatment of these 2 potent cyto-
kines. When the Pao2, MPO, and inflammatory cytokine
results are examined, a synergistic benefit is seen with
cotransfection. This probably reflects the fact that IL-10 and
TGF-1 work at different points in the inflammatory path-
way.12,29 MPO was significantly reduced in the cotrans-
fected and vIL-10 groups compared with the reduction in
the control groups. Yet the reduction in MPO is more
marked with cotransfection compared with use of vIL-10
alone. This leads one to believe that TGF-1 augments
IL-10 expression, leading to increased IL-10 levels and
accounting for the observed difference in cotransfected an-
imals. This also implies that TGF-1 indirectly reduces
MPO activity in the cotransfection group through its effect
on IL-10 expression. Arterial oxygenation is also superior
with cotransfection versus use of either cytokine alone.
With IL-1, either cytokine alone was unable to signifi-
cantly reduce its expression, but cotransfection was success-
ful in returning the level to that of normal control lungs.
Similarly for IFN-, vIL-10 and not TGF-1 reduced its
levels, but cotransfection markedly reduced expression
compare with that seen in normal lungs. This also supports
the idea that TGF-1 augments IL-10 expression, account-
ing for the greater reduction in IFN- levels in cotransfected
animals. The IL-2 level was significantly reduced with
IL-10, TGF-1, and cotransfection. Interestingly, IL-2 ex-
pression was higher in normal flushed lungs compared with
in the 3 study groups. This means that either the flushing
process increased IL-2 or that IL-10, TGF-1, and cotrans-
fection all effectively reduced IL-2 levels to below baseline.
In conclusion, recipient intramuscular gene transfer of
IL-10 and TGF-1 attenuates I/R injury. The plasmid-me-
diated gene cotransfection achieved not only gene expres-
sion but also beneficial immunologic effects by providing a
synergistic effect that significantly improved lung function
after prolonged cold ischemia. Multiple gene transfer of
anti-inflammatory cytokines might not only reduce I/R in-
jury but also might have an effect on preventing acute and
chronic rejection in the transplant setting. These possibili-
ties will be examined in future studies.
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Discussion
Dr W. Roy Smythe (Houston, Tex). Dr Patterson and his
colleagues should be congratulated for continuing to push molec-
ular techniques into the area of lung transplantation.
I have a couple of questions. First, for clinical applications,
how are you going to apply this to patients who only know 6 to 8
hours before transplant that they are going to get a graft? Second,
have you considered putting IL-10 or TGF- into an adeno-
associated virus, so that you could actually dose an experimental
animal or an individual weeks or months ahead of time and still have
the salutary effect when a donor organ was identified? Third, follow-
ing up on that question, if a longer-term expression is desired or
possible, are there any toxic effects of long-term overexpression?
Dr Daddi. Thank you Dr Smythe for your comments. In
response to the first question, we agree that 48 hours before
transplant for vector administration is not entirely useful for clin-
ical application at this time. Two immediate uses for this approach
are in living lobar lung transplantation and acute rejection. We are
testing in our laboratory the effect of adenoviral vectors encoding
TGF- and human IL-10 in the acute rejection setting. Preliminary
data confirm the anti-inflammatory effect on the transplanted graft.
Ideally, this will lead us to further investigations on the molecular
mechanisms involved in lung transplantation.
For the second question, we have not used or considered using
adeno-associated virus for long-term use in our model. It is a very
good idea worth examining further.
For the third question regarding long-term problems with over-
expression of these cytokines, we have not detected any to date.
We confirm that compared with the first-generation adenoviral
vectors, naked plasmid elicits lower plasma expression, yet in
comparison, it is nontoxic to the recipient. We also reasonably
think that because of the nontoxicity of this vector, it should be
applicable in clinical trials involving organ transplantation. Giving
several injections of naked plasmid alone or in combination with
adenoviral vector administration might be a useful therapeutic
instrument. Using the plasmids 1 to 2 days or perhaps 5 days after
transplantation might benefit the lung graft, and we are studying
some protocols about performing this. On the other hand, you
asked me whether there are any side effects of the naked plasmid
on animals. We saw that there was no side effect of the naked
plasmid in the postoperative period in the study groups, and we
noted no postoperative complications. No preoperative or postop-
erative mortality occurred. Morbidity was related to the control
groups. Unfortunately, our I/R injury model does not give us the
possibility to investigate the long-term expression. Data from
similar expression work that we conducted on day 7 with intra-
muscular injection of naked plasmid encoding CAT shows sys-
temically a very mild level of protein expression and no side
effects. Your comment is an interesting one and should be inves-
tigated further.
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